
## Gilberto Betancor Quintana

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7443491/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Longitudinal observation and decline of neutralizing antibody responses in the three months following SARS-CoV-2 infection in humans. Nature Microbiology, 2020, 5, 1598-1607.	13.3	1,115
2	Evaluating the Effects of SARS-CoV-2 Spike Mutation D614G on Transmissibility and Pathogenicity. Cell, 2021, 184, 64-75.e11.	28.9	843
3	SARS-CoV-2 evolution during treatment of chronic infection. Nature, 2021, 592, 277-282.	27.8	802
4	Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study. Lancet Infectious Diseases, The, 2022, 22, 35-42.	9.1	612
5	Changes in symptomatology, reinfection, and transmissibility associated with the SARS-CoV-2 variant B.1.1.7: an ecological study. Lancet Public Health, The, 2021, 6, e335-e345.	10.0	269
6	Comparative assessment of multiple COVID-19 serological technologies supports continued evaluation of point-of-care lateral flow assays in hospital and community healthcare settings. PLoS Pathogens, 2020, 16, e1008817.	4.7	105
7	Immunoproteasome activation enables human TRIM5α restriction of HIV-1. Nature Microbiology, 2019, 4, 933-940.	13.3	54
8	Multiple components of the nuclear pore complex interact with the amino-terminus of MX2 to facilitate HIV-1 restriction. PLoS Pathogens, 2018, 14, e1007408.	4.7	43
9	Oligomerization Requirements for MX2-Mediated Suppression of HIV-1 Infection. Journal of Virology, 2016, 90, 22-32.	3.4	41
10	HIV-1 reverse transcriptase connection subdomain mutations involved in resistance to approved non-nucleoside inhibitors. Antiviral Research, 2011, 92, 139-149.	4.1	38
11	Mechanisms Involved in the Selection of HIV-1 Reverse Transcriptase Thumb Subdomain Polymorphisms Associated with Nucleoside Analogue Therapy Failure. Antimicrobial Agents and Chemotherapy, 2010, 54, 4799-4811.	3.2	29
12	The GTPase Domain of MX2 Interacts with the HIV-1 Capsid, Enabling Its Short Isoform to Moderate Antiviral Restriction. Cell Reports, 2019, 29, 1923-1933.e3.	6.4	27
13	Real-world evaluation of a novel technology for quantitative simultaneous antibody detection against multiple SARS-CoV-2 antigens in a cohort of patients presenting with COVID-19 syndrome. Analyst, The, 2020, 145, 5638-5646.	3.5	26
14	Resilient SARS-CoV-2 diagnostics workflows including viral heat inactivation. PLoS ONE, 2021, 16, e0256813.	2.5	23
15	Effects of HIV-1 reverse transcriptase connection subdomain mutations on polypurine tract removal and initiation of (+)-strand DNA synthesis. Nucleic Acids Research, 2015, 43, 2259-2270.	14.5	22
16	Combined epidemiological and genomic analysis of nosocomial SARS-CoV-2 infection early in the pandemic and the role of unidentified cases in transmission. Clinical Microbiology and Infection, 2022, 28, 93-100.	6.0	21
17	A376S in the Connection Subdomain of HIV-1 Reverse Transcriptase Confers Increased Risk of Virological Failure to Nevirapine Therapy. Journal of Infectious Diseases, 2011, 204, 741-752.	4.0	19
18	Effects of Inner Nuclear Membrane Proteins SUN1/UNC-84A and SUN2/UNC-84B on the Early Steps of HIV-1 Infection. Journal of Virology, 2017, 91, .	3.4	18

#	Article	IF	CITATIONS
19	MX2-mediated innate immunity against HIV-1 is regulated by serine phosphorylation. Nature Microbiology, 2021, 6, 1031-1042.	13.3	18
20	Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy. Retrovirology, 2012, 9, 68.	2.0	7
21	Clinical utility of targeted SARS-CoV-2 serology testing to aid the diagnosis and management of suspected missed, late or post-COVID-19 infection syndromes: Results from a pilot service implemented during the first pandemic wave. PLoS ONE, 2021, 16, e0249791.	2.5	6
22	Molecular basis of the association of H208Y and thymidine analogue resistance mutations M41L, L210W and T215Y in the HIV-1 reverse transcriptase of treated patients. Antiviral Research, 2014, 106, 42-52.	4.1	3
23	The GTPase Domain of MX2 Interacts with HIV-1 Capsid Enabling Its Short Isoform to Moderate Antiviral Restriction. SSRN Electronic Journal, 0, , .	0.4	Ο